A significant breakthrough in neurogenetics has revealed that men who carry two copies of a specific genetic variant are twice as likely to develop dementia during their lifetime compared to women. The study, which analyzed extensive health data from thousands of older adults, sheds new light on the complex interplay between genetics, gender, and neurodegenerative disease, potentially opening doors for more targeted screening and personalized preventative care.
The findings, published in the prestigious medical journal Neurology, focus on the haemochromatosis (HFE) gene. While this gene is primarily known for its role in regulating iron levels within the human body, researchers have long suspected it might play a more clandestine role in brain health. By analyzing the genetic profiles and health outcomes of a massive cohort of elderly participants, the research team identified a stark disparity in how certain mutations of this gene affect the cognitive health of men versus women.
At the heart of the study is a variant known as H63D. The HFE gene is responsible for producing a protein that sits on the surface of cells and helps regulate the amount of iron that enters them. When this gene is mutated, it can lead to a condition known as haemochromatosis, where the body absorbs and stores too much iron, potentially damaging organs such as the liver and heart. However, the H63D variant is often considered a "milder" mutation compared to others associated with iron overload. Despite this reputation, the new research suggests that its impact on the brain may be far more significant than previously understood.
Professor John Olynyk, a co-author of the study from the Curtin Medical School, highlighted the prevalence of this genetic marker within the general population. According to the research, approximately one in three individuals carries a single copy of the H63D variant. While carrying one copy is common, it does not appear to negatively impact an individual’s health or elevate their risk for cognitive decline. The concern lies with those who inherit two copies of the variant—one from each parent.
"Having just one copy of this gene variant does not impact someone’s health or increase their risk of dementia," Professor Olynyk explained. "However, having two copies of the variant more than doubled the risk of dementia in men, but not women."
The discovery that this risk is gender-specific is one of the most striking aspects of the study. For reasons that researchers are still working to uncover, the presence of the double H63D variant appears to create a vulnerability in the male brain that is not mirrored in females. This statistical divergence suggests that biological or hormonal factors unique to men may interact with the genetic variant to accelerate the onset of dementia.
The research was made possible through the use of data from the ASPirin in Reducing Events in the Elderly (ASPREE) trial. ASPREE was a landmark, double-blind, randomized, placebo-controlled trial that monitored 19,114 healthy older individuals across Australia and the United States. While the primary objective of the ASPREE trial was to evaluate whether a daily low dose of aspirin could prolong healthy life in the elderly, the study inadvertently created an immense and invaluable repository of data. By tracking the health, genetics, and lifestyle factors of nearly 20,000 people over several years, the trial has provided a "treasure trove" of information that continues to fuel secondary research into the mechanisms of aging.
By mining this data, the collaborative team of researchers from Curtin University, Monash University, The University of Melbourne, and several other leading Australian medical institutions was able to isolate the impact of the H63D variant with a high degree of statistical confidence. The scale of the ASPREE cohort allowed the team to look past general trends and identify specific risks associated with rare genetic combinations, such as the one in 36 people who carry two copies of the H63D variant.
One of the most surprising findings of the study involves the role of iron itself. Given that the HFE gene is the primary regulator of iron, the researchers initially expected to find that high iron levels in the blood were the smoking gun linking the genetic variant to dementia. However, the data told a different story.
"While the HFE gene is critical for controlling iron levels in the body, we found no direct link between iron levels in the blood and increased dementia risk in affected men," Professor Olynyk said. This finding is significant because it suggests that the H63D variant may be causing damage through pathways that are independent of systemic iron levels. Rather than a simple case of "iron poisoning" the brain, the mutation may be triggering more localized and complex cellular issues.
"This points to other mechanisms at play, possibly involving the increased risk of brain injury from inflammation and cell damage in the body," Professor Olynyk added. If the variant leads to chronic low-grade inflammation or makes brain cells more susceptible to oxidative stress, it could explain the gradual neurodegeneration observed in these patients. Understanding these specific pathways is now a priority for the research team, as it could lead to the development of therapies designed to counteract the damage caused by the variant.
The implications for public health are substantial, particularly regarding how the medical community approaches genetic screening. In many Western countries, including Australia, testing for the HFE gene is already a routine part of clinical practice when a patient is suspected of having haemochromatosis. Because the test is already established and widely available, the researchers suggest it could be utilized more broadly to identify men who are at a higher risk for cognitive decline.
"Our findings suggest that perhaps this testing could be offered to men more broadly," Professor Olynyk noted. By identifying high-risk individuals decades before the onset of symptoms, clinicians might be able to implement preventative strategies, monitor cognitive health more closely, and eventually provide targeted treatments as they become available.
The need for such personalized approaches is underscored by the growing prevalence of dementia globally and within Australia. Currently, more than 400,000 Australians are living with dementia. While the disease is often associated with women due to their longer average lifespans, men account for approximately one-third of all cases. For these men, understanding the genetic drivers of their condition is a critical step toward better care.
Professor Paul Lacaze, a co-author from Monash University, emphasized that the ultimate goal of the research is to improve the lives of those currently at risk. "Understanding why men with the double H63D variant are at higher risk could pave the way for more personalised approaches to prevention and treatment," Professor Lacaze said. He noted that the study serves as a prime example of the power of institutional collaboration. By bringing together experts from Curtin University, Monash, the University of Melbourne, The Royal Children’s Hospital, Murdoch Children’s Research Institute, and Fiona Stanley Hospital, the project was able to bridge the gap between genomic science and clinical application.
Despite the clarity of the increased risk found in the study, many questions remain. Chief among them is the "why" behind the gender disparity. Why does the double H63D variant act as a catalyst for dementia in men while remaining seemingly benign in women? Future research will need to investigate whether estrogen provides a protective effect for women or if there are specific environmental or lifestyle factors more common in men that activate the latent risk of the gene.
Furthermore, the researchers are keen to explore the "brain pathways" Professor Olynyk mentioned. If the damage is not caused by blood iron levels, identifying the exact molecular triggers—whether they be inflammatory cytokines or specific types of cellular oxidative stress—will be essential for developing pharmacological interventions.
"While the genetic variant itself cannot be changed, the brain pathways which it affects—leading to the damage that causes dementia—could potentially be treated if we understood more about it," Professor Olynyk said. This outlook offers a glimmer of hope: while we cannot yet edit the genetic code of every individual at risk, we may soon be able to block the biological consequences of that code.
As the global population ages, the burden of dementia on healthcare systems and families continues to grow. This study marks a vital step forward in deconstructing the "one-size-fits-all" approach to dementia research. By identifying a specific genetic profile that doubles the risk for a significant portion of the male population, researchers are moving closer to a future where neurological health is managed with the same precision as cardiovascular or oncological health.
The collaboration between these Australian research giants highlights the country’s leading role in healthy aging research. Through the continued analysis of the ASPREE data and follow-up studies into the H63D variant, the medical community moves one step closer to unraveling the mysteries of the aging brain and protecting the cognitive health of future generations of men.
